Oncopeptides

Oncopeptides EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncopeptides (ONCO.ST) as of Nov 10, 2026 is -228.93 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -273.75 M SEK — a change of -16.37% (higher).

EBITDA

-228.93 MSEK

YoY

-16.37%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncopeptides is 2025 -228.93 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncopeptides was 2024 -273.75 M SEK. It decreases by -16.37% higher compared to the previous year.

The Oncopeptides EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-420.14 M SEK
Jan 1, 2019
-739.39 M SEK
Jan 1, 2020
-1.59 B SEK
Jan 1, 2021
-1.42 B SEK
Jan 1, 2022
-349.35 M SEK
Jan 1, 2023
-242.41 M SEK
Jan 1, 2024
-273.75 M SEK
Jan 1, 2025
-228.93 M SEK
The Oncopeptides EBITDA history
YEAREBITDAYoY
-228.93 MSEK-16.37%
-273.75 MSEK+12.93%
-242.41 MSEK-30.61%
-349.35 MSEK-75.41%
-1.42 BSEK-10.69%
-1.59 BSEK+115.17%
-739.39 MSEK+75.99%
-420.14 MSEK+69.67%
-247.62 MSEK+116.30%
-114.48 MSEK+114.62%
-53.34 MSEK+61.14%
-33.10 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncopeptides Stock analysis

What does Oncopeptides do? Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncopeptides stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncopeptides is -228.93 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncopeptides changed from -273.75 M SEK to -228.93 M SEK, representing a -16.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Oncopeptides since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Oncopeptides historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oncopeptides

All Key Metrics — Oncopeptides